Comment from GSK
GSKSupportBusiness
Summary: GSK supports the FAA's proposed rule to restrict unmanned aircraft near fixed-site facilities but argues that the eligibility criteria should be expanded to include pharmaceutical research and development (R&D) and manufacturing facilities. They also recommend creating different types of flight restrictions that prohibit loitering while still permitting flyovers to balance security with the right of transit.
GSK appreciates the opportunity to respond to the Federal Aviation Administration’s (FAA) Designation-Restrict the Operation of Unmanned Aircraft in Close Proximity to a Fixed Site Facility proposed rule.
We support the intent of FAA’s proposed rule to restrict the operation of unmanned aircraft near fixed-site facilities to enhance the security, safety, and resilience of infrastructure critical to national public health and safety and respectfully offer the following recommendations.
FAA should amend the proposed rule to expand the Healthcare and Public Health Sector eligibility criteria in Subpart C to permit pharmaceutical research and development (R&D) and manufacturing facilities that are critical to national public health and safety to be eligible to apply for Unmanned Aircraft Flight Restrictions (UAFRs).
FAA should consider different types of UAFRs, such as UAFRs that prohibit loitering while permitting flyovers.
Please see our attached comments for additional detail and justification.